Downstream Bioprocessing Market Overview
Downstream bioprocessing involves a number of products such as chromatography columns and resins, filters, membrane adsorbers, single-use products, and other products (consumables and instruments). Columns and resins are the most important components of a chromatography system and are extensively used in the separation, recovery, and purification of components of a bioactive sample. In addition, different samples in the drug development phase require different types of columns for separation, and these columns have to be frequently changed to optimize the stationary phase. Also, for the purpose of purification, resins need to be repurchased.
Moreover, biopharmaceutical companies are increasingly preferring single-use downstream bioprocessing systems, including filters, cartridges, and chromatographic columns, with the aim of improving process efficiency and decreasing the costs associated with complicated steps like cleaning, sterilization, and maintenance of steel-based bioreactor systems. The single-use downstream bioprocessing technology is used in a broad range of biopharmaceutical applications, including filtration, purification, storage, and separation. Most biopharmaceuticals require bioprocessing systems for large-scale production, which in turn necessitates the use of bioprocessing systems with better process efficiency and throughput.
The demand for biopharmaceutical products is expected to increase across the globe inline with the rising geriatric population and the subsequent growth in the prevalence of chronic diseases. As a result of the growing demand for biopharmaceuticals, and increasing focus on ensuring the quality of products to be launched in the market, the significance of the downstream bioprocessing market is increasing in the biopharmaceutical industry.
The downstream bioprocessing market is a technology-driven market, marked with a high degree of competition among key players. Prominent players in the market include Merck Millipore, GE Healthcare, Sartorius Stedim Biotech S.A., Thermo Fisher Scientific Inc., Danaher Corporation, 3M Company, Boehringer Ingelheim, Lonza Group AG, Eppendorf AG, and Finesse Solutions, Inc. Players implemented various strategies to maintain their positions and ensure long-term growth in the market. The key strategies adopted by most of the companies in the downstream bioprocessing market include product launches, new service launches, product enhancements, collaborations, acquisitions, expansions, and others (investment, and website launches).
Biopharmaceutical manufacturing companies around the world are implementing these technologically advanced products in their downstream processing, which inducing the growth of downstream processing market over the next few years. According to a research study published by MarketsandMarkets the global downstream bioprocessing market is expected to reach USD 22.03 billion by 2021 from USD 10.32 billion in 2016, at a CAGR of 16.4% during the forecast period of 2016 to 2021. Growth in this market is mainly driven by the increasing demand for biopharmaceuticals and increasing R&D expenditure in the biopharmaceutical industry.
To learn more about the assumptions considered for the study, download the PDF Brochure